These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7734946)

  • 1. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.
    Black LE; Farrelly JG; Cavagnaro JA; Ahn CH; DeGeorge JJ; Taylor AS; DeFelice AF; Jordan A
    Antisense Res Dev; 1994; 4(4):299-301. PubMed ID: 7734946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018.
    Rogers H; Adeniyi O; Ramamoorthy A; Bailey S; Pacanowski M
    Clin Transl Sci; 2021 Mar; 14(2):468-475. PubMed ID: 33278337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory IND: a new regulatory strategy for early clinical drug development in the United States.
    Sarapa N
    Ernst Schering Res Found Workshop; 2007; (59):151-63. PubMed ID: 17117721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory concerns for the chemistry, manufacturing, and controls of oligonucleotide therapeutics for use in clinical studies.
    Kambhampati RV; Chiu YY; Chen CW; Blumenstein JJ
    Antisense Res Dev; 1993; 3(4):405-10. PubMed ID: 8155982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory toxicology perspectives on the development of botanical drug products in the United States.
    Wu KM; Farrelly J; Birnkrant D; Chen S; Dou J; Atrakchi A; Bigger A; Chen C; Chen Z; Freed L; Ghantous H; Goheer A; Hausner E; Osterberg R; Rhee H; Zhang K
    Am J Ther; 2004; 11(3):213-7. PubMed ID: 15133537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration.
    Dodson A; Mi K; Russo DP; Scott C; Saulnier M; Snyder K; Racz R
    J Pharmacol Toxicol Methods; 2021; 111():107098. PubMed ID: 34229067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
    Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
    Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
    Senderowicz AM
    Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application.
    Gobburu JV; Sekar VJ
    Int J Clin Pharmacol Ther; 2002 Jul; 40(7):281-8. PubMed ID: 12139204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
    Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
    J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory science: a special update from the United States Food and Drug Administration: Preclinical issues and status of investigation of botanical drug products in the United States.
    Wu KM; DeGeorge JG; Atrakchi A; Barry E; Bigger A; Chen C; Du T; Freed L; Geyer H; Goheer A; Jacobs A; Jean D; Rhee H; Osterberg R; Schmidt W; Farrelly JG
    Toxicol Lett; 2000 Jan; 111(3):199-202. PubMed ID: 10643863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.